Jianmin Pharmaceutical Group Co.Ltd(600976) announced on January 3 that recently, it was learned from the website of the State Drug Administration that qiruiweishu capsule developed by the company was approved for listing. This product is an innovative traditional Chinese medicine developed on the basis of preparations in medical institutions. It can be used for the treatment of epigastric pain caused by mild to moderate chronic non atrophic gastritis with erosion damp heat and blood stasis syndrome.
(interface News)
